Opthea Limited (OPT.AX)
| Previous close | 0.4050 |
| Open | 0.4150 |
| Bid | 0.4100 x 0 |
| Ask | 0.4150 x 0 |
| Day's range | 0.4000 - 0.4200 |
| 52-week range | 0.3125 - 0.8150 |
| Volume | |
| Avg. volume | 1,974,842 |
| Market cap | 295.044M |
| Beta (5Y monthly) | 0.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings date | 29 Aug 2024 - 02 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Oct 2004 |
| 1y target est | 5.90 |
GlobeNewswireOpthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
Dr. Arshad Khanani to chair the newly formed Medical Advisory BoardMELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board (“MAB”) composed of 10 retina thought leaders from
- GlobeNewswire
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows successful Institutional Entitlement Offer and institutional Placement raising approximately A$171.5m (US$113.2m1) Completion of Retail Entitlement Offer represents final stage of Opthea’s approximately A$227.3m (US$150.0m1) capital raising MELBOURNE, Australia, and PRINCETON, N.J., July 15, 2024 (GL
- GlobeNewswire
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal Ophthalmology and Therapy MELBOURNE, Australia and PRINCETON, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-relat
